Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey

References

• International Diabetes Federation. www.idf.org; 2016. Available at: https://www.idf.org/node/23533 [Last accessed 17 March 2016]
   Google Scholar
• International Diabetes Federation. About diabetes. www.idf.org; 2016:1–3. Available at: http://www.who.int/diabetes/action_online/basics/en/index.html [Last accessed 17 March 2016]
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015. Available at: http://www.diabetesatlas.org/key-messages.html [Last accessed 17 March 2016]
   Google Scholar
• Rhee E-J, Park SE, Chang Y, et al. Baseline glycemic status and mortality in 241,499 Korean metropolitan subjects: a Kangbuk Samsung health study. Metabolism 2016;65:68-77
   PubMed Web of Science ®Google Scholar
• World Health Organization. Diabetes Fact Sheet. 2010. Available at: http://www.who.int/nmh/publications/fact_sheet_diabetes_en.pdf [Last accessed 17 March 2016]
   Google Scholar
• Apovian CM. Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes Metab Syndr Obes 2011;4:353-69
   PubMedGoogle Scholar
• Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications 2015;29:295-301
   PubMed Web of Science ®Google Scholar
• Taylor R. Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes. Diabet Med 2013;30:267-75
   PubMed Web of Science ®Google Scholar
• Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991;34:891-8
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes – 2016. Diabetes Care 2016;39(Suppl1):S1-S110
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ 2008;34:511-17
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther 2014;5:225-42
   PubMed Web of Science ®Google Scholar
• Perez-Nieves M, Kabul S, Desai U, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Curr Med Res Opin 2016;32:669-80
   PubMed Web of Science ®Google Scholar
• Hadjiyianni I, Desai U, Suzuki S, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in Japan. Diabetes Ther 2017;8:149-66
   PubMed Web of Science ®Google Scholar
• Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naive type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence 2015;9:1225-31
   PubMed Web of Science ®Google Scholar
• Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: a systematic review of the literature. Diabetes Educ 2016;42:34-71
   PubMed Web of Science ®Google Scholar
• Ayyagari R, Wei W, Cheng D, et al. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health 2015;18:198-205
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-71
   PubMed Web of Science ®Google Scholar
• Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589-600
   PubMed Web of Science ®Google Scholar
• Baser O, Tangirala K, Wei W, et al. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res 2013;5:497-505
   PubMedGoogle Scholar
• Kalra S. Newer basal insulin analogues: degludec, detemir, glargine. J Pak Med Assoc 2013;63:1442-4
   PubMed Web of Science ®Google Scholar
• Eliaschewitz FG, Barreto T. Concepts and clinical use of ultra-long basal insulin. Diabetol Metab Syndr 2016;8:2
   PubMed Web of Science ®Google Scholar
• Pscherer S, Chou E, Dippel FW, et al. Treatment persistence after initiating basal insulin in type 2 diabetes patients: a primary care database analysis. Prim Care Diabetes 2015;9:377-84
   PubMed Web of Science ®Google Scholar
• Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231-8
   PubMed Web of Science ®Google Scholar
• Wang L, Wei W, Miao R, et al. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open 2013;3:e002348. doi:10.1136/bmjopen-2012-002348
   Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-9
   PubMed Web of Science ®Google Scholar
• Kostev K, Dippel FW, Rathmann W. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care. Prim Care Diabetes 2016;10:142-7
   PubMed Web of Science ®Google Scholar
• Hadjiyianni I, Peyrot M, Ivanova J, et al. Reasons behind different patterns of basal insulin persistence among people with type 2 diabetes: findings from multi-national interviews. Diabet Med 2016;33:154-6
   Web of Science ®Google Scholar
• Hadjiyianni I, Peyrot M, Ivanova J, et al. Basal insulin initiation experience among people with type 2 diabetes mellitus (T2DM): findings from multi-national interviews. SPEDM Congresso Portugues de Endocrinologia Annual Meeting, Coimbra, Portugal, 28-30 January 2016. Available at: http://www.congressoportuguesdeendocrinologia.com/2016/index.htm [Last accessed 30 March 2016]
   Google Scholar
• Blak BT, Smith HT, Hards M, et al. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012;29:e13-20
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Menditto LA, Ulcickas Yood M, et al. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin 2007;23:3105-12
   PubMed Web of Science ®Google Scholar
• Wei W, Pan C, Xie L, et al. Real-world insulin treatment persistence among patients with type 2 diabetes. Endocr Pract 2014;20:52-61
   PubMed Web of Science ®Google Scholar
• Levin PA, Zhou S, Gill J, et al. Health outcomes associated with initiation of basal insulin after 1, 2, or ≥3 oral antidiabetes drug(s) among managed care patients with type 2 diabetes. J Manag care Spec Pharm 2015;21:1172-81
   PubMed Web of Science ®Google Scholar
• Baruch Y, Holtom BC. Survey response rate levels and trends in organizational research. Hum Relations 2008;61:1139-60
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Mean and Median Age at Diagnosis of Diabetes Among Adult Incident Cases Aged 18–79 years, United States, 1997–2011. Diabetes Public Health Resource. 2015. Available at: http://www.cdc.gov/diabetes/statistics/age/fig2.htm [Last accessed 6 June 2016]
   Google Scholar
• Hays RD, Liu H, Kapteyn A. Use of Internet panels to conduct surveys. Behav Res Methods 2015;47:685-90
   PubMed Web of Science ®Google Scholar
• Craig BM, Hays RD, Pickard AS, et al. Comparison of US panel vendors for online surveys. J Med Internet Res 2013;15:e260
   PubMed Web of Science ®Google Scholar